Don Schneider, Piper Sandler deputy head of U.S. policy, joins CNBC's 'The Exchange' to discuss portfolio positioning ahead ...

Fintel reports that on November 8, 2024, Piper Sandler upgraded their outlook for Upstart Holdings (NasdaqGS:UPST) from ...

Piper Sandler analyst Michael Lavery maintained a Sell rating on Beyond Meat (BYND – Research Report) today and set a price target of $3.00. The company’s shares closed yesterday at $6.58. According ...

SolarEdge Technologies rebounds after Trump administration fears, but Q3 loss and forecasted revenue decline raise concerns.

Piper Sandler raised the firm’s price target on Amplitude (AMPL) to $11 from $9 and keeps a Neutral rating on the shares. The firm said ...

Expectations for President-elect Donald Trump to roll out expansionary fiscal policies and extend U.S. economic ...

Piper Sandler raises Fastly target to $8; keeps Neutral rating. Fastly's Q3 EPS beats estimates, revenue slightly misses ...

Celanese downgraded at Piper Sandler, citing uncertain business environment and financial strain ahead with a precarious condition of the balance sheet.

Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for ...

Such findings raised questions about the added benefit of masofaniten, leading ESSA to abandon the drug’s development. In light of these results, Piper Sandler removed any projected value for ...

Piper Sandler Companies (NYSE:PIPR – Get Free Report) last issued its quarterly earnings data on Friday, October 25th.The financial services provider reported $2.57 earnings per share for the ...

On Tuesday, Piper Sandler began coverage of CAMP4 Therapeutics Corp (NASDAQ:CAMP) stock with an Overweight rating and a price target of $18.00. The firm highlighted CAMP4's innovative work in the ...